BCL2 and acute myeloid leukemia: IDH1 and 2-mutant primary human AML cells were more sensitive than IDH1/IDH2-WT AML cells to ABT-199, a specific BCL-2 inhibitor, by inhibiting cytochrome c oxidase in the mitochondrial ETC [171].